Odalade Overdosage

Overdosing: The overall risk of exposure is limited.
Mild to moderate poisoning: It is anticipated that toxicity is likely an extension of pharmacologic events which may include the development of thrombocytosis, hepatotoxicity, bone marrow reticulin formation and bone marrow fibrosis. Rash, bradycardia, elevated aminotransferase concentrations, and thrombocytosis have been reported after overdose.
Severe poisoning: An excessive increase in platelet count may increase the risk of developing a thrombotic and/or thromboembolic events.
Treatment: In the event of overdose, platelet counts may increase excessively and result in thrombotic/thromboembolic complications. In case of an overdose, oral administration of a metal cation containing preparation, such as calcium, aluminium, or magnesium preparations to chelate eltrombopag and thus limit absorption should be considered. Platelet counts should be closely monitored. Treatment with eltrombopag should be reinitiated in accordance with dosing and administration recommendations.
Because eltrombopag is not significantly renally excreted and is highly bound to plasma proteins, hemodialysis would not be expected to be an effective method to enhance the elimination of eltrombopag.